Biochemistry and Molecular Biology

Joseph Delaney, Ph.D.

Our lab pursues translational oncology. We determine which aneuploid events in cancer are most likely driving tumor biology and design novel therapies based on these changes. While we work with many types of cancer, our primary model is high-grade serous ovarian cancer, due to its unusually high rate of therapy. We are currently pursuing a PhaseI/II clinical trial with the Hollings Cancer Center investigating autophagy drug combinations, which may be active Spring 2022. Please see our website, The Delaney Lab for more information on our research.

David Thomas Long, Ph.D.

Associate Professor and Director of Graduate Training Department of Biochemistry and Molecular Biology
Office: BSB 518A, Lab: BSB 517

The Long laboratory uses Xenopus egg extracts in combination with traditional cellular and biochemical approaches to study the role that chromatin signaling plays in regulating major DNA transactions like transcription, replication, and DNA repair. Our laboratory specializes in the breast and ovarian cancer tumor suppressor BRCA1, which acts as a "master regulator" of genomic integrity. Although BRCA1 and associated factors are known drivers of tumor development, the underlying mechanisms remain enigmatic. Please visit our website, The David Thomas Long Lab, for more information.

Jennifer Stancill, Ph.D.

Assistant Professor of Biochemistry and Molecular Biology
Office: CRI 513, Lab: CRI 504F

The Stancill lab is interested in understanding the mechanisms used by pancreatic beta-cells to protect themselves from damaging agents and how these mechanisms might be disrupted during the pathogenesis of diabetes mellitus. We study the ways beta-cells detoxify reactive oxygen species and are specifically focused on the thioredoxin/peroxiredoxin antioxidant pathway. We use mouse and human islets as our primary model systems combined with a number of molecular and biochemical approaches. Please check out our website for more information about our research.